수술 후 통증에 대한 리도카인 주입의 장기 결과(LOLIPOP) 시험 (LOLIPOP)
The LOLIPOP Trial is a large (n=4,300 patients) pragmatic, international, multicentre, prospective, randomised, double blind, placebo-controlled, parallel assessment, safety and effectiveness superiority study.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
The Trial's purpose is to evaluate the effectiveness of lidocaine infusions commenced during surgery and extending up to 24 hours postoperatively, on the incidence of moderate or severe chronic post-surgical pain (CPSP) detected one year following surgery in female patients undergoing elective breast cancer surgery. The trial has 90% power to detect a clinically meaningful (25%) reduction in the incidence of the primary outcome. Secondary outcomes include safety events, analgesic efficacy (pain scores and opioid consumption), neuropathic characteristics of CPSP, and psychological and quality of life outcomes.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Gillian Ormond
- 전화번호: +610399030387
- 이메일: gillian.ormond@monash.edu
연구 연락처 백업
- 이름: Natalie Hird
- 전화번호: +61 (0) 459 407 231
- 이메일: natalie.hird@health.wa.gov.au
연구 장소
-
-
Auckland
-
Auckland, Auckland, 뉴질랜드, 1023
- 모병
- Auckland City Hospital
-
-
Middlemore
-
Auckland, Middlemore, 뉴질랜드, 2025
- 모병
- Middlemore Hospital
-
-
Waikato Region
-
Hamilton, Waikato Region, 뉴질랜드, 3204
- 모병
- Waikato Hospital
-
-
-
-
-
Belfast, 영국, BT9 7AB
- 모병
- Belfast City Hospital
-
Bristol, 영국, BS10 5NB
- 모병
- Southmead Hospital, North Bristol Trust
-
Darlington, 영국, DL3 6HX
- 종료됨
- Darlington Memorial Hospital
-
Dudley, 영국, DY1 2HQ
- 모병
- Russells Hall Hospital
-
Liverpool, 영국
- 모병
- Royal Liverpool and Broadgreen Hospitals
-
London, 영국, N19 5NF
- 모병
- Whittington Hospital
-
London, 영국
- 모병
- Royal Marsden Hospital - London and Sutton
-
Newcastle upon Tyne, 영국
- 모병
- Newcastle upon Tyne Hospitals
-
Norwich, 영국, NR4 7UY
- 모병
- Norfolk and Norwich University Hospital
-
Rotherham, 영국, S60 2UD
- 모병
- Rotherham NHS Foundation Trust
-
Sheffield, 영국, S10 2JF
- 모병
- Royal Hallamshire Hospital
-
Southampton, 영국
- 모병
- University Hospital Southampton
-
St Helens, 영국, WA9 3DA
- 모병
- St Helen's Hospital
-
Torquay, 영국, TQ2 7AA
- 모집하지 않고 적극적으로
- Torbay Hospital
-
Winchester, 영국, SO22 5DG
- 모병
- Royal Hampshire County Hospital
-
-
Scotland
-
Wishaw, Scotland, 영국
- 모병
- University Hospital Wishaw
-
-
-
-
New South Wales
-
Kingswood, New South Wales, 호주, 2747
- 모병
- Nepean Hospital
-
Mount Druitt, New South Wales, 호주, 2770
- 모병
- Blacktown Mount Druitt Hospital
-
Sydney, New South Wales, 호주, 2217
- 모병
- St George Hospital
-
Sydney, New South Wales, 호주, 2145
- 완전한
- Westmead Hospital
-
Sydney, New South Wales, 호주, 2035
- 모병
- Royal North Shore Hospital
-
-
Queensland
-
Brisbane, Queensland, 호주, 4029
- 완전한
- Royal Brisbane and Women's Hospital
-
Coopers Plains, Queensland, 호주, 4108
- 모집하지 않고 적극적으로
- Queen Elizabeth II Jubilee Hospital
-
Mackay, Queensland, 호주, 4740
- 모집하지 않고 적극적으로
- Mackay Base Hospital
-
Rockhampton, Queensland, 호주, 4700
- 완전한
- Rockhampton Hospital
-
Southport, Queensland, 호주, 4215
- 완전한
- Gold Coast Hospital and Health Service- Gold Coast University Hospital
-
Woolloongabba, Queensland, 호주, 4102
- 모병
- Princess Alexandra Hospital
-
-
South Australia
-
Bedford Park, South Australia, 호주, 5042
- 모병
- Flinders Medical Centre
-
-
Tasmania
-
Hobart, Tasmania, 호주, 7000
- 모병
- Royal Hobart Hospital
-
-
Victoria
-
Ballarat, Victoria, 호주, 3350
- 완전한
- Anaesthetic Group Ballarat
-
Ballarat, Victoria, 호주, 3350
- 모집하지 않고 적극적으로
- Ballarat Health Services (Grampians Health)
-
Geelong, Victoria, 호주, 3220
- 모병
- Barwon Health - University Hospital Geelong
-
Melbourne, Victoria, 호주, 3065
- 모병
- St Vincent's Hospital Melbourne
-
Melbourne, Victoria, 호주, 3004
- 모병
- The Alfred
-
Melbourne, Victoria, 호주, 3050
- 모집하지 않고 적극적으로
- Royal Melbourne Hospital
-
Melbourne, Victoria, 호주, 3165
- 완전한
- Monash Health - Moorabbin Hospital
-
Melbourne, Victoria, 호주, 3076
- 빼는
- Northern Hospital
-
Ringwood East, Victoria, 호주, 3135
- 모병
- Maroondah Hospital - Eastern Health
-
Shepparton, Victoria, 호주, 3630
- 완전한
- Goulburn Valley Health
-
Traralgon, Victoria, 호주, 3844
- 빼는
- Latrobe Regional Hospital
-
-
Western Australia
-
Bentley, Western Australia, 호주, 6102
- 모병
- Bentley Health Service
-
Perth, Western Australia, 호주, 6000
- 모병
- Royal Perth Hospital
-
Perth, Western Australia, 호주, 6008
- 모병
- St John of God Subiaco
-
-
-
-
-
Chai Wan, 홍콩
- 모병
- Pamela Youde Nethersole Eastern Hospital
-
Wan Chai, 홍콩
- 모병
- Ruttonjee Hospital
-
-
Sha Tin
-
Shatin, Sha Tin, 홍콩
- 모병
- North District Hospital
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Consenting adult female patients (≥18 years) undergoing mastectomy (unilateral or bilateral) or breast conserving surgery (unilateral or bilateral) for the primary excision of confirmed or suspected primary breast cancer under general anaesthesia (including those with simultaneous insertion of tissue expanders or implants)*. * this specifically excludes patients undergoing surgery for locoregional recurrence
- American Society of Anaesthesiologist (ASA) physical scale 1-3
Exclusion Criteria:
- Mastectomy or breast conserving surgery with add on procedures e.g laparoscopic salpingectomy
- Where surgery is being performed for locoregional recurrence of breast cancer
- Pre-existing pain at site of surgery, axilla, ipsilateral side of chest wall or the ipsilateral upper arm (at diagnosis prior to any tumor locating procedures)
- Re-excision procedures where the margins at the index surgery have been deemed insufficient
- When immediate autologous reconstruction surgery is planned
- Where delayed autologous reconstruction surgery on the operative breast within one year is planned
- Planned use of regional analgesia infusions
- Impaired cognition
- Pregnant or lactating females
- Transgender patients
- Known metastatic disease
- History of anaphylaxis, sensitivity or known contraindication to lidocaine (or other amide local anaesthetic agents e.g. other amide local anaesthetic agents: ropivacaine, bupivacaine, mepivacaine, prilocaine, etidocaine), including patients with porphyria or methaemoglobinaemia
- History of epilepsy
- Baseline heart rate < 50 bpm or systolic blood pressure < 100mmHg.
- Acute coronary event in the last three months
- Cardiac conduction abnormalities, including; Atrial fibrillation, Heart block (all degrees), Bundle Branch Block or Fascicular block, Prolonged QT interval, Wolf Parkinson White syndrome, channelopathy such as Brugada syndrome. A preoperative Electrocardiogram (ECG) is not mandatory, unless clinically indicated
- Abnormal serum potassium concentration (based upon site laboratory reference ranges)
- Active liver disease e.g. viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, haemochromatosis, other rarer causes)
- Medications within the last 7 days which are known / suspected to slow lidocaine metabolism (amiodarone, beta blockers, cimetidine, fluoroquinolones, fluvoxamine, imidazoles, macrolides, verapamil, HIV drugs)
- Cardiac Failure (any documented heart failure at peroperative assessment or GP records)
- Severe Renal Failure (Creatinine Clearance of less than 30ml/min or dialysis dependent)
- Co-administration of lidocaine within 24 hours prior to surgery for other reasons (e.g. lidocaine patches
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
활성 비교기: Lidocaine
2% Lidocaine infusion intra-operative and 10% Lidocaine infusion post-operative. |
Lidocaine infusion:
다른 이름들:
|
|
위약 비교기: Placebo
0.9% Saline infusion intra-operative and 0.9% Saline infusion post-operative. |
Placebo infusion:
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
The incidence of moderate or severe CPSP at 1 year after surgery, as reported by the patient at the follow-up review.
기간: 1 year post-surgery
|
Numerical rating scale ≥4 out of 10 for worst pain in the last week - The pain must have been present for at least 3 months prior to the one year assessment (or longer). |
1 year post-surgery
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
The incidence of severe CPSP at 1 year after surgery
기간: 1 year post surgery
|
NRS for worst pain the in the last week of ≥7) |
1 year post surgery
|
|
Severity of pain at the site of surgery
기간: 1 year post surgery
|
Assessed using "average" and "worst" NRS pain score in the last week, obtained from the adapted modified Brief Pain Inventory-Short Form (mBPI-SF) |
1 year post surgery
|
|
Incidence of neuropathic symptoms
기간: 1 year post surgery
|
Incidence examined as a binary outcome using the Short Form of Douleur Neuropathique 4 Questions (S-DN4) |
1 year post surgery
|
|
Physical functioning
기간: 1 year post surgery
|
Using interference component of mBPI-SF |
1 year post surgery
|
|
Changes in quality of life metrics EuroQol 5 Dimension 5 Level (EQ-5D-5L) at 1 year after surgery compared to baseline
기간: 1 year post surgery
|
Changes in the quality of life |
1 year post surgery
|
|
Changes in psychological wellbeing Kessler Psychological Distress Scale (K-10) at 1 year after surgery compared to baseline.
기간: 1 year post surgery
|
Changes in psychological wellbeing |
1 year post surgery
|
|
The incidence of mild or greater pain at the site of surgery at 1 year after surgery
기간: 1 year post surgery
|
NRS for worst pain the in the last week of ≥1 |
1 year post surgery
|
|
The incidence of discomfort or altered sensation at the site of surgery (not reported as pain)
기간: 1 year post surgery
|
Patients asked if they have any altered sensation at the site of surgery |
1 year post surgery
|
|
Severity of acute postoperative pain at rest
기간: 24 hours postoperatively
|
Maximum pain score, Numerical rating scale (NRS) 0-10 |
24 hours postoperatively
|
|
Severity of Acute postoperative pain on movement
기간: 24 hours postoperatively
|
Maximum pain score, Numerical rating scale (NRS) 0-10 |
24 hours postoperatively
|
|
Postoperative opioid consumption
기간: on Day 1
|
Morphine Equivalent Opioid Consumption (MEQ) |
on Day 1
|
|
Postoperative opioid consumption
기간: 3 months (last 24-hours)
|
Morphine Equivalent Opioid Consumption (MEQ) |
3 months (last 24-hours)
|
|
Postoperative opioid consumption
기간: 1 year post surgery (last 24 hours)
|
Morphine Equivalent Opioid Consumption (MEQ) |
1 year post surgery (last 24 hours)
|
|
The incidence of mortality at 1 year
기간: 1 year post surgery
|
Mortality at 1 year |
1 year post surgery
|
|
UK NHS costs of care over 1 year following surgery
기간: 1 year post surgery
|
UK/NHS sites only |
1 year post surgery
|
|
Productivity costs over 1 year following surgery
기간: 1 year post surgery
|
UK/NHS sites only |
1 year post surgery
|
|
Quality-adjusted life years (QALYs) over 1 year following surgery
기간: 1 year post surgery
|
UK/NHS sites only |
1 year post surgery
|
|
Cost-effectiveness of perioperative lidocaine infusions compared to usual care, from a primary UK NHS perspective and broader perspective including productivity, at 1 year.
기간: 1 year post surgery
|
UK/NHS sites only |
1 year post surgery
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of treated bradycardia intraoperatively
기간: 24 hours postoperatively
|
Drug related safety Endpoints |
24 hours postoperatively
|
|
Incidence of treated hypotension intraoperatively
기간: 24 hours postoperatively
|
Drug related safety Endpoints |
24 hours postoperatively
|
|
Incidence of treated bradycardia in Post Anaesthesia Care Unit (PACU)
기간: 24 hours postoperatively
|
Drug related safety Endpoints |
24 hours postoperatively
|
|
Incidence of treated hypotension in Post Anaesthesia Care Unit (PACU)
기간: 24 hours postoperatively
|
Drug related safety Endpoints |
24 hours postoperatively
|
|
Incidence of intraoperative infusion stopping events
기간: 24 hours postoperatively
|
Drug related safety Endpoints |
24 hours postoperatively
|
|
Incidence of Post Anaesthesia Care Unit (PACU) infusion stopping events
기간: 24 hours postoperatively
|
Drug related safety Endpoints, (x2 symptoms, x1 sign, x1 complication) |
24 hours postoperatively
|
|
Incidence of postoperative infusion stopping events on the ward
기간: 24 hours postoperatively
|
Drug related safety Endpoints, (x2 symptoms, x1 sign, x1 complication) |
24 hours postoperatively
|
|
Incidence of suspected lidocaine toxicity events
기간: 24 hours postoperatively
|
Drug related safety Endpoints |
24 hours postoperatively
|
|
Incidence of suspected SEVERE lidocaine toxicity events
기간: 24 hours postoperatively
|
Drug related safety Endpoints, (generalised seizure, sudden unexplained LOC, life-threatening arrhythmia, or asystole, cardiac or circulatory arrest) |
24 hours postoperatively
|
|
Incidence of Medical Emergency Team (MET) activation
기간: 24 hours postoperatively
|
Drug related safety Endpoints |
24 hours postoperatively
|
|
Incidence of unplanned Intensive Care Unit (ICU), High Dependency Unit (HDU) or Critical Care Unit (CCU) admission
기간: 24 hours postoperatively
|
Drug related safety Endpoints |
24 hours postoperatively
|
|
Incidence of study drug unblinding events
기간: 24 hours postoperatively
|
Drug related safety Endpoints |
24 hours postoperatively
|
|
Incidence of subcutaneous catheter site events
기간: Day 30
|
Drug related safety Endpoints |
Day 30
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Tomas Corcoran, Royal Perth Hospital
간행물 및 유용한 링크
일반 간행물
- Toner AJ, Bailey MA, Schug SA, Corcoran TB. A pilot multicentre randomised controlled trial of lidocaine infusion in women undergoing breast cancer surgery. Anaesthesia. 2021 Oct;76(10):1326-1341. doi: 10.1111/anae.15440. Epub 2021 Mar 2.
- Toner AJ, Bailey MA, Schug SA, Phillips M, Ungerer JP, Somogyi AA, Corcoran TB. Serum lidocaine (lignocaine) concentrations during prolonged perioperative infusion in patients undergoing breast cancer surgery: A secondary analysis of a randomised controlled trial. Anaesth Intensive Care. 2023 Nov;51(6):422-431. doi: 10.1177/0310057X231194833. Epub 2023 Oct 6.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- HREC/74777/Alfred-2021
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .